The impact of obstructive sleep apnoea on the aorta

Thomas Gaist¹, Daniel J. Bratton¹ and Malcolm Kohler¹,²,³

Affiliations:
¹Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
²Centre for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
³Centre for Interdisciplinary Sleep Research, University of Zurich, Zurich, Switzerland.

Correspondence:
Malcolm Kohler, Dept of Pulmonology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
E-mail: Malcolm.Kohler@usz.ch

ABSTRACT Obstructive sleep apnoea (OSA) has been shown to be a causal factor in the pathogenesis of vascular dysfunction and hypertension, conditions which can promote dilation and subsequent aortic dissection and rupture. The objective of this review is to summarise the current literature on the possible association between OSA and aortic disease and delineate the underlying mechanisms.

Relevant studies were found by searching for terms including “obstructive sleep apnoea” in combination with “aortic aneurysm, dissection, and dilation” in the MEDLINE and EMBASE databases.

Observational studies consistently reported that OSA is highly prevalent among patients with aortic aneurysms and aortic dissections. Patients with co-occurring OSA and Marfan’s syndrome as well as patients at the more severe end of the spectrum of OSA seem to be especially vulnerable to aortic disease.

Several mechanisms are discussed concerning the link between OSA and aortic disease: nocturnal negative intrathoracic pressure surges leading to mechanical stretching of the aorta and ultimately aortic distension; arousal-induced reflex sympathetic activation with subsequent hypertension; and intermittent hypoxia associated with autonomic nervous system activation and consequently increased oxidative stress. Further well controlled studies are needed in order to define the exact role of OSA as a risk factor for aortic disease.

@ERSpublications
Several studies have shown an association between obstructive sleep apnoea and aortic aneurysms/dissections http://ow.ly/Nh9jc

This article has supplementary material available from erj.ersjournals.com

Received: Feb 20 2015 | Accepted after revision: April 29 2015

Support statement: This review was funded by the Clinical Research Priority Program (CRPP) Sleep and Health from the University of Zurich. Funding information for this article has been deposited with FundRef.

Conflict of interest: None declared.

Copyright ©ERS 2015
Introduction

Obstructive sleep apnoea (OSA) is highly prevalent, with at least 20% of males and 10% of females in Western countries affected by asymptomatic OSA [1–4]. Pathophysiologically, the disease is characterised by repetitive partial or complete obstruction of the pharynx during sleep. Despite increasing breathing efforts the upper airway collapse results in episodes of obstructive hypopnoeas or apnoeas affecting the sleep architecture and the whole body via instant and long-term mechanisms.

Determining the potential contribution of OSA to cardiovascular risk is challenging. A large proportion of research on OSA is dedicated to cardiovascular consequences, where a causal relationship between OSA, major adverse cardiovascular events [5–7], heart failure [5] and mortality [8] has been suggested yet not definitely established. By contrast, OSA has been confirmed to be a causal factor in the pathogenesis of vascular dysfunction and hypertension [9, 10]. Cohort studies including the Sleep Heart Health Study have consistently demonstrated that over 50% of individuals with OSA have hypertension [1, 11, 12]. Sustained and effective treatment of OSA with continuous positive airway pressure (CPAP) has been reported to improve daytime symptoms and quality of life [13, 14] and to reduce blood pressure [15], one of the major risk factors for aortic dilation [16].

An aortic aneurysm is defined as a permanent, localised dilation of the aorta that includes all three layers of the vessel [17]. The prevalence of thoracic aortic aneurysms (TAA) and abdominal aortic aneurysms (AAA) is 0.16–0.34% [18, 19] and 1.2% [20], respectively, with a markedly higher prevalence in men aged >60 years. Currently, aortic aneurysms in general represent the 18th leading cause of death in the USA [21]. Pathogenesis and treatment differ slightly for aortic aneurysms depending on the exact location [22]; however, about 25% of patients with TAA also have AAA, suggesting similar risk factors for both diseases [23]. Aortic aneurysms represent a group of disorders resulting from connective tissue diseases, inflammatory components [24], hypertension and atherosclerosis [23, 25] and are associated with high rates of morbidity and mortality due to dissection and/or rupture [23, 26]. Besides the treatment of the underlying risk factors, elective repair of large-diameter aneurysms and aneurysms with a high expansion rate is recommended. Because aneurysms are usually asymptomatic, a timely detection and knowledge of the underlying risk factors is crucial.

The potential impact of OSA on cardiovascular burden and aortic disease is likely to be related in large part to its association with elevated blood pressure. Ambulatory blood pressure is particularly elevated during sleep compared with the awake period and OSA patients often present a non-dipping pattern (diminished nocturnal blood pressure fall) or riser pattern (sleep blood pressure higher than awake blood pressure) of nocturnal blood pressure [27]. Regardless of how blood pressure is measured, there is a significant association between OSA severity and elevated blood pressure [28]. It is generally accepted that hypertension can cause thoracic aortic dilation [29] and is the main risk factor for aortic dissection (AD) [26], although the exact pathophysiology remains unclear. Chronic hypertension and its vascular consequences are major yet fractional risk factors, since it is not rare for aortic disease to also develop in adequately treated patients [22, 30]. It is therefore thought that OSA may act through a number of other pathomechanisms to elicit vascular damage. However, because of the association between common risk factors (e.g. age, male sex, hypertension, etc.) and both OSA [1, 31–33] and aortic disease [23, 25, 30], it is difficult to establish the true effect of OSA.

The purpose of this review is to summarise the clinical evidence and synthesise the pathophysiological mechanisms between OSA and aortic disease, namely: 1) aortic dilation, 2) aortic aneurysms (TAA and AAA), and 3) AD. The aim is to provide clinicians with a clear picture of the current literature on this topic, discuss potential implications for clinical practice and highlight areas of future research for this highly prevalent sleep disorder.

Methods

Inclusion criteria

Studies were eligible if they covered (at least in one aspect) the topic of the impact of OSA on aortic disease (aortic dilation, AD, TAA, AAA) or vice versa. Studies in humans and in English published until January 1, 2015 were considered for this review. We did not include case reports, reviews, conference abstracts and studies investigating aortic stiffness. No other restrictions were used.

Search strategy

We performed electronic database searches in MEDLINE (Ovid version, New York, NY, USA) and EMBASE (DataStar Version, Cary, NC, USA). The search was conducted using the following medical subject heading (MeSH) terms: “obstructive sleep apnea” in combination with “aortic dilatation”, “aortic aneurysm” and “aortic dissection”, including alternative MeSH entry terms. The bibliographies of all
articles that fulfilled the inclusion criteria were screened to identify other articles that fulfilled the inclusion criteria.

Results
Searches of electronic databases identified 23 eligible studies with a total of 2800 patients. Figure 1 shows the flow diagram for identification of relevant studies. Complete search results are available in the online supplementary material (table S1). In this results section, the evidence from clinical studies on the impact of OSA on aortic disease will be reviewed, followed by a discussion of the potential underlying mechanisms.

Evidence from clinical studies on the impact of OSA on aortic disease
Marfan’s syndrome
Research on the impact of OSA on aortic disease is based upon early studies in patients with Marfan’s syndrome. Marfan’s syndrome is a genetic multisystem connective tissue disorder associated with craniofacial abnormalities and increased upper airway collapsibility, both of which are linked to OSA [34–37]. Aortic dilation and associated AD and rupture are the main cause of morbidity and mortality in patients with Marfan’s syndrome, cutting life expectancy by about one third compared with the general population [38, 39]. In 1993, it was first suspected by Cistulli and Sullivan [40] that OSA might have deleterious effects on aortic dilation and subsequent rupture. They attributed, at least in part, the reduced life expectancy due to aortic complications to the high OSA prevalence among patients with Marfan’s syndrome [40]. Later, a considerably high OSA prevalence in patients with Marfan’s syndrome was confirmed and a moderate correlation between the apnoea–hypopnoea index (AHI) and maximal aortic root diameter was found (r=0.5, p<0.001, 95% CI 0.2–0.69) [41, 42]. A follow-up study in 44 patients with

FIGURE 1 Flow diagram for identification of relevant studies.
Marfan’s syndrome was then performed to further explore the longitudinal association between OSA and aortic disease [43]. After a median follow-up time of 29 months, only subjects with OSA developed an aortic event, defined as an operation because of progressive aortic dilation or death because of aortic rupture. The AHI was associated with aortic events in univariable analysis (hazard ratio 1.09, 95% CI 1.01–1.18), but not when other covariates (age, sex, systolic blood pressure, antihypertensive medication, baseline aortic diameter) were accounted for, possibly due to a lack of statistical power [43]. Up to now, this represents the only longitudinal study where the impact of OSA on aortic disease (by means of events rather than disease parameters) has been investigated.

### General population

Studies in the general population show a somewhat mixed body of evidence (table 1). Most of the studies investigated the association between OSA and the aortic root diameter [44–52]. Six cross-sectional studies investigating patients referred for a sleep evaluation reported a positive association between the aortic root diameter and parameters of OSA severity (either AHI or oxygen desaturation index (ODI)) [45, 48–52]. Notably, one study found an association with AHI in rapid eye movement sleep only where the severity of OSA becomes greater, partly due to a decreased respiratory muscle tone [52]. Another study reported this association in patients with hypertrophic cardiomyopathy [48].

By contrast, two prospective [44, 47] and one retrospective study [46] did not establish the aforementioned relationship. TANRIVERDI et al. [44] reported no difference in aortic diameters (systolic/diastolic) in a matched OSA case–control study. This finding is in agreement with another retrospective study that assessed aortic diameter in 76 OSA patients and found age and sex to be the only determinants for aortic root dilation [46]. However, 84% of these patients were treated with CPAP, which is likely to dilute the association between AHI and aortic diameter [46]. Another study investigated patients with acute myocardial infarction for an association between OSA and aortic diameter [47]. Stepwise multivariable regression revealed that body mass index (BMI), age and hypertension, but not AHI, showed an independent relationship with thoracic aortic diameter [47]. A somewhat different picture emerged, however, if OSA patients were subdivided into AHI groups. Compared with controls, only severe OSA patients (AHI >30 events·h\(^{-1}\)) had a larger aortic diameter (p=0.048) [47]. One could therefore hypothesise that the adverse impact of OSA on the aorta only deploys above a certain AHI threshold, which is possibly higher than the common diagnostic threshold of AHI ≥5 events·h\(^{-1}\).

Another study retrospectively assessed computed tomography-derived abdominal aortic diameters at three anatomic locations in 427 subjects. After adjusting for major AAA risk factors, OSA (defined as AHI ≥10 events·h\(^{-1}\)) was an independent risk factor for distal abdominal aortic dilation in men [53].

### Prevalence of OSA among aortic disease patients

In 2003, SAMPOL et al. [54] reported a higher AHI in 19 patients with AD compared with 19 controls matched for age, sex and BMI (p=0.032). Although the OSA prevalence (defined by AHI >5 events·h\(^{-1}\)) did not differ between AD patients and the matched control group (68% in each group), their findings are largely attributable to the high number (n=7) of severe OSA cases in the AD group versus one case in the control group (p=0.042). In other words, AD patients presented a higher burden of nocturnal apnoic events and severe OSA (defined by AHI >30 events·h\(^{-1}\)). Similar case–control studies also reported higher percentages of moderate to severe ODI in AD patients versus controls [55, 56] and two other studies concluded that AD is associated with OSA [57, 58]. These findings raise the question of whether a high AHI/severe OSA is also more prevalent in other forms of aortic disease.

An international multicentre study found that ~40% of patients aged 18–75 years in an AAA surveillance register presented with an AHI >10 events·h\(^{-1}\) [59]. Cross-sectional data indicated no association of aortic diameter with AHI [59]. In order to investigate a possible association between OSA/AHI and rate of AAA expansion, MASON et al. [59] assessed patients with AAA during a median follow-up interval of 18 months. From the total cohort (n=127), patients with severe forms of OSA (ODI >30 events·h\(^{-1}\)) had a significantly faster median yearly AAA expansion rate than patients with ODI <5 events·h\(^{-1}\) (p=0.05), independent of cardiovascular risk markers [59]. Other studies using indirect measures of OSA (Berlin Questionnaire) reported that about 60% of AAA patients are likely to have OSA [60]. Finally, SARUHARA et al. [61] conducted a case–control study where TAA, AAA and AD patients were found to have a higher incidence of moderate to severe OSA (AHI >15 events·h\(^{-1}\)) than controls. Table 2 summarises studies on the prevalence of OSA among aortic disease patients.

### Physiological studies in healthy volunteers

Three studies have investigated the pathophysiological effects of OSA using breathing manoeuvres that simulate OSA features in healthy volunteers (table 3) [62–64]. The Müller manoeuvre (simulated
Obstructive apnoea (OSA) has proven to be an elegant way to partially simulate acute effects of OSA without the confounding factors of profound hypoxaemia, arousals from sleep and comorbidities often present in patients with OSA [65]. In humans, the Müller manoeuvre and simulated obstructive hypopnoea (inspiration through threshold load) induced considerable changes in blood pressure and simulated obstructive hypopnoea has been shown to be associated with an increase in proximal aortic diameter and aortic area [62, 64]. The underlying forces of this increase were quantified in a second study, which concluded that simulated obstructive apnoea/hypopnoea increased aortic wall dilatory pressures [63].

<table>
<thead>
<tr>
<th>First author [ref.]</th>
<th>Year</th>
<th>Design</th>
<th>Population</th>
<th>Subjects n</th>
<th>Outcome measures</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tanriverdi [44]</td>
<td>2006</td>
<td>Case–control</td>
<td>Sleep laboratory</td>
<td>40, plus 24 controls</td>
<td>IMT, FMD, aortic stiffness</td>
<td>OSA is associated with higher values of aortic stiffness and IMT but lower distensibility and FMD (including data on aortic diameter)</td>
</tr>
<tr>
<td>Serizawa [45]</td>
<td>2008</td>
<td>Cross-sectional</td>
<td>Sleep laboratory</td>
<td>150</td>
<td>AHI, aortic diameter</td>
<td>AHI is independently associated with greater thoracic aortic diameter</td>
</tr>
<tr>
<td>Meuleman [46]</td>
<td>2008</td>
<td>Cross-sectional</td>
<td>Sleep laboratory</td>
<td>76</td>
<td>AHI, aortic diameter, aortic stiffness</td>
<td>The prevalence of aortic root dilation in OSA is 3.9%; no association between OSA and aortic parameters</td>
</tr>
<tr>
<td>Kohler [41]</td>
<td>2009</td>
<td>Case–control</td>
<td>Marfan’s syndrome</td>
<td>61, plus 26 controls</td>
<td>OSA prevalence, correlation of AHI and aortic diameter</td>
<td>OSA is highly prevalent in Marfan’s syndrome; AHI correlates with aortic diameter</td>
</tr>
<tr>
<td>Lee [47]</td>
<td>2010</td>
<td>Cross-sectional</td>
<td>Acute myocardial infarction</td>
<td>94</td>
<td>AHI, aortic root</td>
<td>BMI, age and hypertension, but not AHI, determine thoracic aortic size</td>
</tr>
<tr>
<td>Pedrosa [48]</td>
<td>2010</td>
<td>Case–control</td>
<td>HCM</td>
<td>32, plus 48 controls</td>
<td>Left atrial diameter, aortic diameter</td>
<td>OSA is highly prevalent in HCM patients and is associated with left atrial and aortic enlargement</td>
</tr>
<tr>
<td>Cicek [49]</td>
<td>2011</td>
<td>Cross-sectional</td>
<td>Sleep laboratory</td>
<td>90</td>
<td>AHI, aortic root size, left ventricle dysfunction</td>
<td>Severity of OSA (AHI) correlates with aortic root diameter</td>
</tr>
<tr>
<td>Achrour [50]</td>
<td>2011</td>
<td>Cross-sectional</td>
<td>General population</td>
<td>303</td>
<td>Mean nocturnal oxygen saturation, aortic root</td>
<td>Nocturnal hypoxaemia is associated with aortic root size in the elderly</td>
</tr>
<tr>
<td>Baguet [51]</td>
<td>2011</td>
<td>Cross-sectional</td>
<td>Sleep laboratory</td>
<td>156</td>
<td>Aortic root, nocturnal hypoxia, diastolic blood pressure, AHI, BRS</td>
<td>Nocturnal hypoxaemia, decreased BRS and increased diastolic BP are associated with greater aortic root size in OSA</td>
</tr>
<tr>
<td>Kohler [43]</td>
<td>2013</td>
<td>Prospective cohort</td>
<td>Marfan’s syndrome</td>
<td>44</td>
<td>Aortic events</td>
<td>Aortic event-free survival may be shorter in patients with Marfan’s syndrome and OSA compared with patients without OSA</td>
</tr>
<tr>
<td>Chen [52]</td>
<td>2014</td>
<td>Case–control</td>
<td>Sleep laboratory</td>
<td>65, plus 14 controls</td>
<td>Cardiac function, aortic root</td>
<td>Patients with moderate to severe OSA tend to have cardiac dysfunction (including data on aortic diameter)</td>
</tr>
<tr>
<td>Tachikawa [53]</td>
<td>2014</td>
<td>Cross-sectional</td>
<td>Sleep laboratory</td>
<td>427</td>
<td>Abdominal aortic diameter at three anatomic landmarks</td>
<td>OSA is independently associated with dilation of the distal abdominal aorta in men</td>
</tr>
</tbody>
</table>

IMT: carotid intima-media thickness; FMD: flow-mediated dilation; AHI: apnoea–hypopnoea index; BMI: body mass index; HCM: hypertrophic cardiomyopathy; BRS: baroreflex sensitivity; BP: blood pressure.
### TABLE 2 Prevalence of obstructive sleep apnoea (OSA) among aortic disease patients

<table>
<thead>
<tr>
<th>First author [ref.]</th>
<th>Year</th>
<th>Design</th>
<th>Population</th>
<th>Subjects n</th>
<th>Outcome measures</th>
<th>Prevalence of OSA in given population</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAMPOL [54]</td>
<td>2003</td>
<td>Case–control</td>
<td>AD</td>
<td>19, plus 19 controls</td>
<td>AHI in patients with AD</td>
<td>68% (AHI &gt;5 events·h(^{-1}))</td>
<td>AD is associated with a higher AHI</td>
</tr>
<tr>
<td>MASON [59]</td>
<td>2010</td>
<td>Cross-sectional</td>
<td>AAA</td>
<td>127</td>
<td>AAA prevalence and progression rate</td>
<td>41.5% (AHI &gt;10 events·h(^{-1}))</td>
<td>OSA is highly prevalent in AAA; severe OSA is associated with a faster AAA expansion</td>
</tr>
<tr>
<td>NAITO [55]</td>
<td>2011</td>
<td>Case–control</td>
<td>AD</td>
<td>29, plus 59 controls</td>
<td>ODI in patients with AD</td>
<td>75.9% (ODI ≥15 events·h(^{-1}))</td>
<td>A high ODI/IHR is associated with AD</td>
</tr>
<tr>
<td>HATA [58]</td>
<td>2011</td>
<td>Cross-sectional</td>
<td>AD</td>
<td>139</td>
<td>Sleep apnoea syndrome</td>
<td>61.4% (AHI &gt;5 events·h(^{-1}))</td>
<td>Sleep apnoea syndrome, insomnia and sleep deprivation are highly prevalent in patients with AD aged &lt;65 years</td>
</tr>
<tr>
<td>SARUHARA [61]</td>
<td>2012</td>
<td>Case–control</td>
<td>TAA, AAA, AD</td>
<td>95, plus 32 controls</td>
<td>Prevalence of OSA</td>
<td>48.4% (AHI ≥15 events·h(^{-1}))</td>
<td>Moderate and severe OSA are more prevalent in TAA, AAA and AD</td>
</tr>
<tr>
<td>YANAGI [57]</td>
<td>2013</td>
<td>Cross-sectional</td>
<td>AD</td>
<td>95</td>
<td>Prevalence of OSA</td>
<td>12.6% (clinical suspicion and AHI ≥5 events·h(^{-1}))</td>
<td>Patients who have AD with OSA are characterised by being tall, fat and relatively young men with hypertension</td>
</tr>
<tr>
<td>BIANCHI [60]</td>
<td>2014</td>
<td>Cross-sectional</td>
<td>AAA</td>
<td>302</td>
<td>Risk of OSA in elderly AAA patients</td>
<td>60.6% (BQ)</td>
<td>Elderly AAA patients are at high risk for cardiometabolic disease and OSA according to the BQ</td>
</tr>
<tr>
<td>ZHANG [56]</td>
<td>2014</td>
<td>Case–control</td>
<td>AD (type B)</td>
<td>82, plus 116 controls</td>
<td>Prevalence of OSA</td>
<td>81.7% (AHI ≥5 events·h(^{-1}))</td>
<td>OSA is highly prevalent and independently associated with AD (type B)</td>
</tr>
</tbody>
</table>


### TABLE 3 Experimental studies on the association between obstructive sleep apnoea (OSA) and aortic disease in healthy volunteers

<table>
<thead>
<tr>
<th>First author [ref.]</th>
<th>Year</th>
<th>Subjects n</th>
<th>Outcome measures</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>STÖWHAS [62]</td>
<td>2011</td>
<td>20</td>
<td>Thoracic aortic diameter during simulated OSA measured via ultrasonography</td>
<td>Simulated hypopnoea increases proximal aortic diameter by +6.5% (± 3.03, p=0.007) and reduces blood pressure in the aortic root by −10.5 mmHg (± 2.2 mmHg, p=0.001); blood pressure also increased significantly on release of simulated OSA</td>
</tr>
<tr>
<td>CLARENbach [63]</td>
<td>2013</td>
<td>10</td>
<td>Thoracic aortic transmural pressure (aortic mean blood pressure minus oesophageal pressure) during simulated OSA</td>
<td>Simulated obstructive apnoea induced median +16.3 mmHg (IQR 12.8–19.4 mmHg; p=0.02) extra aortic dilatory force because intra-aortic pressures fall less than oesophageal pressures</td>
</tr>
<tr>
<td>RAMMOHAN [64]</td>
<td>2014</td>
<td>6</td>
<td>Thoracic aortic area during simulated OSA measured via ultrasonography</td>
<td>Simulated obstructive apnoea increases aortic area by a mean ± SD of +0.43±0.08 cm(^2) (p=0.002)</td>
</tr>
</tbody>
</table>

IQR: interquartile range.
Current limitations of published studies

The aforementioned observational studies demonstrate a great deal of heterogeneity in study design approaches and in the populations studied. These variations include, for example, the facts that the treatment status of OSA was not taken into account [46], common diagnostic criteria have not been consistently applied [45, 47, 51] and some studies lacked a control group [46, 58, 60]. In studies assessing the thoracic aorta there is also a high between-study variation in methodological aspects, as studies do not use consistent anatomic landmarks [41, 44–47, 49–51]. When considering conflicting results among thoracic and abdominal diameters measured at different anatomic landmarks and the fact that, even in a single study, aortic diameters at different landmarks were distinctly affected by OSA, one may hypothesise that the aetiopathological significance of OSA may vary along the aorta [53]. Furthermore, specific OSA severity groups are often not reported and are most likely underpowered [41, 44–46, 50, 51, 61]. The latter represents a limitation, as the results of several studies suggest that the more severe end of the OSA spectrum (AHI ≥30 events·h⁻¹) accounts for the impact of OSA on aortic disease [47, 49, 54, 55, 59, 61].

A significant proportion of studies in this review were submitted in the form of short notes [51, 58] or correspondence letters [45, 50], or their main outcome was something other than aortic diameter [44]. Therefore, they were originally designed with an objective other than investigating the association between OSA and aortic dilation. The possibility exists that the initial finding of a statistically significant association between OSA and aortic diameter evoked authors to selectively report their (mostly positive [45, 50, 51, 58]) data, thus creating a publication bias. Finally, studies on the prevalence of aortic disease in OSA patients are lacking. This makes it difficult to assess the actual overall impact of OSA on aortic disease.

Besides Marfan’s syndrome, there are other heritable connective tissue disorders (e.g. Ehlers–Danlos syndrome and Loeys–Dietz syndrome) that are associated with aortic complications [66–69]. However, studies on the prevalence of OSA and the impact of OSA on aortic disease in these conditions are lacking. Nevertheless, it is important to keep in mind that patients with connective tissue disorders are prone to developing OSA, in general due to alterations affecting the pharyngeal soft tissue. However, because of the different pathophysiology these patients may not be representative for the usual OSA patient group.

Potential mechanisms for the association between OSA and aortic disease

The underlying mechanism(s) through which OSA may promote aortic disease and thus be a risk factor for aneurysm development are not fully understood. Studies investigating the impact of OSA on aortic disease have discussed several pathomechanisms (for thoracic aorta, see figure 2), including intrathoracic pressure changes leading to shear stress on artery walls [41, 43, 49, 51, 54, 55, 62, 63], intermittent hypoxia leading to oxidative stress and sympathetic stimulation [49, 50, 55], and arousal-induced sympathetic activation with subsequent repetitive blood pressure surges [45, 47, 50, 54, 55, 59, 61]. These mechanisms are discussed in the following section.

Intrathoracic pressure changes

Repetitive apnoeic episodes in OSA result in inspiratory effort against the occluded airway, producing negative intrathoracic pressure swings. These forces support (already elevated) blood pressure to stretch the aortic walls where blood pressure surges are highest and lead to pathological shear stress. It is known that systolic blood pressure hastens the fragmentation of fibrin and collagen deposition with secondary stiffening of the aortic wall [47]. Additional physical dilation or shear stress itself might be another important factor for developing atherosclerosis [70].

In animals, increased aortic diameters during obstructive apnoeas have been observed [71, 72]. In humans, the negative end-apnoeic pressures were quantified in one in vivo study (n=74), with a mean of −53.6±2.9 cmH₂O and peak pressure of −147.4 cmH₂O [73]. Compared with physiological inspiration pressure of around −5 to −8 cmH₂O in healthy subjects [74] or nocturnal systolic blood pressure of around 160 cmH₂O (equal to 120 mmHg, which is considered the upper limit for normal nocturnal blood pressure [75]), apnoeic episodes in OSA can involve a substantial amount of energy. One study found that the extent of extra aortic dilatatory force originating from simulated obstructive apnoea was 16.3 mmHg (interquartile range 12.8–19.4 mmHg; p=0.02) [63]. Therefore, a significant proportion of negative pressure is forwarded to the walls of the aorta and OSA may mechanically promote dilation. Negative intrathoracic pressure changes are also thought to contribute to aortic dilation in patients with Marfan’s syndrome [41, 43]. Due to the fact that OSA subgroups are evenly distributed among AD, TAA and AAA patients, mechanisms other than solely thoracic ones must play a role in the pathogenesis of aortic disease in general [61].
Arousal-induced sympathetic activation

In OSA, cessation of the airway flow can last up to 1 min. As a consequence, blood oxygen levels decrease and carbon dioxide levels rise. Each apnoeic event is accompanied by an arousal, which leads to large transient increases in blood pressure ($\sim 80$ mmHg) despite a fall in cardiac output [76]. In OSA these events are caused by sympathetic vasoconstriction [77] and their consequences include catecholamine release [77], endothelial dysfunction [78] and probably aortic disease itself [43, 46, 47, 49, 51]. Although these pathophysiological haemodynamic and neurohumoral changes occur during sleep, their consequences persist for 24 h [79]. Hypertension is present in 72% of AD [26], 60% of TAA [23] and $\sim 75\%$ of AAA [59] patients and there is consensus that the main identified risk factor for aortic dilation is systemic hypertension. Previous studies have shown that increased sympathetic drive in OSA can accelerate atherosclerosis and lead to impairment of the aortic elasticity property in the setting of hypertension [80, 81]. It has also been proposed that increased afterload from OSA-driven systemic hypertension determines aortic diameter [47]. Therefore, acute as well as chronic hypertension represents a crucial and clinically important pathway in the consequences of OSA and pathogenesis of aortic disease.

Interruption hypoxia

The previously described short-term increases in arterial blood pressure at the end of an obstructive apnoea episode are mediated by sympathetic activity [82]. These blood pressure surges seem to be blunted during oxygen administration in OSA patients, suggesting that arterial hypoxaemia influences the autonomous nervous system in OSA patients via chemoreceptors [82]. Hypoxia is associated with the production of reactive oxygen species, which augment pro-inflammatory cytokines and enhance the production of adhesion molecules in endothelial cells/leukocytes, and promote atherosclerosis [83]. In a rodent model, intermittent hypoxia increased chemoreflex and depressed baroreflex, resulting in sympathoadrenal hyperactivity [84]. In humans, intermittent hypoxia due to OSA has been proposed to induce hypertension via increased release of vasoactive substances [85] and peripheral chemoreceptors [86]. In OSA patients, the severity of OSA is independently associated with oxidative stress caused by apnoic events [87]. In several studies, the decrease of arterial oxygen saturation measured by pulse oximetry was correlated with the degree of aortic stiffness, a well-established disease parameter [44, 49]. Hypoxia has also been associated with increased carotid [88] and aortic root diameters [51]. Hence, hypoxia represents a potential contributor to systemic hypertension and atherosclerosis, both of which are mechanisms involved in the development of aortic disease.
**Inflammatory process**

In contrast to the aforementioned mechanisms, the inflammation mechanism is largely theoretical. Although some studies included in this review have considered inflammation as a potential mechanism, none specifically investigated its impact [44, 53, 56, 59, 61].

It has been shown that the formation of some aortic aneurysms is a progressive inflammatory process [24, 89]. Inflammation is thought to orchestrate the various pathophysiological processes that lead to aortic aneurysms in the first place [90]. About 5% of TAA [89] and AAA [24] are inflammatory aneurysms (not to be confused with infected aortic aneurysms), which are characterised by marked aortic wall thickening with increased vascularity. They are considered an extreme form of aneurysm, where inflammation itself represents the dominant factor [24]. Anti-inflammatory drugs such as aspirin have shown promising effects in reducing aortic wall inflammation and growth rate in patients with AAA [91]. Because OSA has been suggested to have a systemic pro-inflammatory effect [92] and directly affects the vascular endothelium by promoting local inflammation [93], it is possible that OSA potentiates aortic dilation via this mechanism.

**Interactions between mechanisms**

The mechanisms described often act via the sympathetic nervous system and acute or chronic elevated blood pressure represents one common pathway. Blood pressure constantly oscillates (systole, diastole) as part of normal heart physiology but additional rises with OSA can cause chronic damage. It is entirely possible for mechanisms to be coupled and act in parallel. For example, negative intrathoracic pressure swings and transient blood pressure surges might synergistically encourage dilation of the aorta (already weakened by factors such as atherosclerosis) several hundred times at night. However, it is important to keep in mind that there are very few observations and high inter-individual variability of both parameters; hence, only a limited group of OSA patients might actually be affected via these mechanisms. Although some clinical studies suggest a common adverse effect of OSA on TAA, AAA and AD [61], one must consider the possibility that the pathophysiology of each disease may differ. This view is encouraged by the fact that TAA, AAA and AD do not share the same risk factors [94]. For example, atherosclerosis is positively associated with AAA [95] while evidence suggests it is negatively associated with TAA [96]. It is crucial to have a detailed knowledge of the underlying pathophysiology so that future treatments will target the right mechanism(s).

**Implications for further research**

**Role of treatment**

The present standard treatment for OSA is CPAP. It has been demonstrated that sustained and effective nocturnal CPAP treatment can lower ambulatory blood pressure, eliminate the ensuing acute haemodynamic changes during sleep and improve early signs of atherosclerosis [15, 81, 97, 98]. Determining whether aortic disease is caused by the acute effects of apnoeic episodes or the chronic structural and autonomic changes resulting from untreated OSA is likely to result in important implications for therapy [99]. In the case of acute events, CPAP treatment of OSA can abolish the acute blood pressure surges and/or intrathoracic pressure swings and lower diurnal blood pressure. However, effective CPAP treatment presents a considerable clinical challenge, as only about 30–60% of patients are adherent to CPAP [100]. Conversely, if long-term autonomic effects of OSA cause major aortic damage, there may be effective alternative therapy approaches to avoid these pathomechanisms, including (in theory) pharmacological modalities and renal sympathetic denervation [99].

In light of the proposed association between OSA and aortic disease, it is reasonable to hypothesise that CPAP might also attenuate (but not reverse) aortic root dilation in Marfan’s syndrome [101, 102] and aortic aneurysm expansion rate [59]. Further steps include determining the value of CPAP treatment in the primary and secondary prevention of aortic disease in OSA patients and assessing the benefits of OSA screening in patients with aortic disease.

**Threshold effect**

The current literature suggests that the adverse impact of OSA on aortic dilation [49], TAA [61], AAA [53, 59, 61] and AD [54, 55, 61] only occurs above a certain severity level between moderate and severe OSA. It appears likely that there is not a straightforward linear dose–response relationship between OSA severity and aortic disease but perhaps a threshold effect [47, 54, 59]. Depending on the proposed underlying mechanisms, other measures of disease severity, such as number of apnoeas per hour, pulse transit time [103] or arousal index, may be alternative or more accurate approaches for identifying patients at risk for aortic dilation. This needs to be further investigated.
Future research

Future studies need to control for additional risk factors (primarily for hypertension) and effect modifiers. Although observational studies have, at least in part, reported an association between OSA and aortic disease, it is too early to presume a causal relationship due to the lack of randomised controlled trials. However, identifying a causal role of OSA on aortic disease is very difficult to establish, since aortic disease is a chronic condition and usually has a very long latent period before the first (and potentially fatal) symptoms emerge. This is aggravated by the fact that the genesis of aortic aneurysms and AD are believed to have multifactorial overlapping risk factors and many of them are overlapping with those of OSA. Finally, a randomised controlled trial faces the ethical issue of treating a high number of OSA patients with sham CPAP for several years.

Based on the current literature, the main points for future research are as follows. 1) The sample size of studies in this field is relatively low. High quality studies with larger sample sizes, especially in the thus far underrepresented severe OSA group (AHI >30 events·h⁻¹), are needed to study a potential minimum threshold level for increased risk of aortic disease. 2) Prevalence studies of aortic disease in OSA patients are lacking. These numbers are needed to further quantify the association between OSA and aortic disease. 3) A further investigation of primary and secondary preventative measures of aortic disease in OSA is required. Randomised controlled trials are needed to potentially assess a causal relationship. 4) Longitudinal studies of disease parameters and clinical outcomes (e.g. aortic events in OSA) are needed in order to assess the potential long-term impact of OSA on aortic disease. 5) Prevalence studies on OSA in conditions associated with aortic problems (e.g. connective tissue diseases other than Marfan’s syndrome) are needed in order to determine the impact of OSA on potentially vulnerable individuals. 6) A meta-analysis of individual patient data from relevant studies is warranted to quantify the association between thoracic aortic root size and the severity of OSA more precisely. 7) A common set of definitions and diagnostic methods for OSA are highly recommended to decrease clinical heterogeneity of studies and allow for a systematic comparison.

Conclusions

Several studies have shown an association between OSA and aortic dilation. OSA has been found to be highly prevalent in patients with aortic aneurysms and severe OSA seems to be associated with more rapid progression of AAA. Possible mechanisms that might promote aortic dilation include intrathoracic pressure changes, repetitive blood pressure surges and chronic hypertension, as well as atherosclerosis induced by intermittent hypoxia. However, there is a need for well-controlled prospective studies in order to establish a causal relationship between OSA and aortic dilation.

References


